Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Ampac Fine Chemicals (AFC), a subsidiary of American Pacific Corporation, has entered into a manufacturing partnership with Codexis, a California-based biotech company.
Subscribe to our email newsletter
As per a new agreement, Ampac Fine Chemicals is expected to use Codexis’ proprietary biocatalysis technology in combination with AFC’s existing technologies to reduce cost, increase manufacturing efficiency and lessen environmental impact for pharmaceutical intermediates and APIs.
Ampac Fine Chemicals said that through this collaboration, it will have access to certain Codexis biocatalysts that add to the technology ‘toolbox’ already present at AFC. Ampac Fine Chemicals and Codexis will focus on development of new chemical processes through this collaboration that, if successful, could result in manufacturing cost reductions on a number of marketed pharmaceutical products.
Aslam Malik, president of AFC, said: “The partnership with Codexis brings the strengths of two innovative companies together to further leverage AFC’s inherent skills. AFC technologies and commercial scale production capabilities have successfully enabled our customers’ projects for over 50 years.”
Joe Carleone, CEO of Ampac, said: “Ampac Fine Chemicals is one of America’s manufacturers of custom small molecule APIs. This partnership with Codexis is another example of the forward looking steps our team has made to serve our customers with the most efficient and cost effective manufacturing processes for their products.”